InflammationINFLAMESNCT06620679
Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men
A study testing Lipopolysaccharide (LPS) in people with Inflammation and Stress, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
Trial summary
The goal of this interventional study is to determine the effects of inflammation on stress responses in the brain of healthy men. In order to achieve this goal, participants are injected with an inflammation-inducing agent, then observed inside a brain scanner. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Inflammation, Stress, Healthy Volunteer
- What is being tested?
- Lipopolysaccharide (LPS)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteBelgium
- Study dates
- 3 May 2024to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male
- Healthy
- Age 18-45 years
- BMI 18.5-25 kg/m2
- Proficient in English and/or Dutch
Who cannot join
- Have previous or current neuropsychiatric disorders or have history of major head trauma
- Have any disorder, which in the Investigator's opinion might jeopardise your safety or compliance with the study
- Have any prior or current treatment(s) that might jeopardise your safety or that would compromise the integrity of the study
- Have any prior and recent medication use (especially antibiotics, cardiovascular drugs, steroids, non-steroid anti-inflammatory drugs, centrally effective drugs)
- Are participating in an interventional Trial with an investigational medicinal product (IMP) or device
- Have current or previous infection or vaccination within the last 8 weeks
Show all 17Show fewer
- Have pathological values of blood indices and certain genetic profiles that will affect brain imaging results (we will conduct a blood screening before starting the study)
- Had strong physical activity (e.g. swimming, football, running more than 8 km per hour, carrying heavy loads) 24h before the start of the experiment.
- Are a smoker
- Are a night-shift worker
- Have recent or previous use of psychotropics within the last year
- Have regular high alcohol use (>4 drinks/week)
- Have any brain imaging contraindications:
- Have claustrophobia or too much uneasiness in limited spaces (in order to tolerate confinement during the scanning procedures).
- Have severe back problems that will interfere with lying on your back in the scanner with no movement for long durations.
- Have any condition that would interfere with MRI studies (e.g., cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, and metallic body inclusion or other metal implanted in the body). To check this, you will need to fill out a checklist before the procedure.
- You and/or your partner is planning to become pregnant during and up to one month of the completion of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
UZ/KU Leuven
Leuven, Flemish Brabant, 3000
Lukas Van Oudenhove, MD, PhD, +3216330147, lukas.vanoudenhove@kuleuven.be
Dina Satriawan, MD, Mnsci, +3216710366, dina.satriawan@kuleuven.be
About this study
The goal of this interventional study is to determine the effects of inflammation on stress responses in the brain of healthy men. In order to achieve this goal, participants are injected with an inflammation-inducing agent, then observed inside a brain scanner.
Read the detailed description
This interventional study is a randomized, triple-blind, placebo-controlled, cross-over study aiming to elucidate the impact of acute laboratory-induced inflammation using lipopolysaccharide (LPS) on stress responses in the brain of healthy men. Acute stress responses to a psychological task, the Maastricht Imaging Stress Task (MIST), are observed via blood-oxygenation-level-dependent functional magnetic resonance imaging (BOLD fMRI) and simultaneous positron emission tomography (PET) imaging using the radiotracer 18 Fluor (18F)-N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-acetamide (DPA)-714, which targets the 18 kilodalton (kDA) translocator protein (TSPO) of activated microglia. Every participant will receive 0.4 ng/kg body weight of LPS and saline on separate treatment visits, separated by a 2-3 months wash-out period.
- Conditions
- Inflammation, Stress, Healthy Volunteer
- Being tested
- Lipopolysaccharide (LPS), Placebo
- Keywords
- Inflammation, Stress, Lipopolysaccharide (LPS), Short-chain fatty acids, Neuroimaging
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lipopolysaccharide (LPS)Biological
Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight
PlaceboOther
Normal saline, single i.v. bolus, in equal volume to intervention
| Study group | Role | What they receive |
|---|---|---|
| LPS then Saline | Experimental | A crossover arm where the participant first receives the intervention (LPS), undergoes a wash-out period, then receives the placebo (saline). Receives: Biological: Lipopolysaccharide (LPS); Other: Placebo |
| Saline then LPS | Experimental | A crossover arm where the participant first receives the placebo (saline), undergoes a wash-out period, then receives the intervention (LPS). Receives: Biological: Lipopolysaccharide (LPS); Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood-oxygenation-level-dependent functional magnetic resonance imaging (BOLD fMRI) response to acute stress task
BOLD fMRI responses to the Montreal Imaging Stress Task (MIST) after administration of LPS compared to saline
Measured: 2 hours after the single i.v bolus administration of LPS or saline
Binding potential of [18F]-DPA-714 radiotracer
The change in [18F]-DPA-714 binding potential with and without LPS administration (%∆BPND)
Measured: 2 hours after the single i.v bolus administration of LPS or saline
Secondary outcomes (15)
Concentration of serum cytokines
Serum samples will be used for the quantification of inflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), interferon-γ (IFN-γ), IL-6, IL-8, IL-1 receptor agonist (RA), IL-4, and IL-10 using the Meso Scale Discovery (MSD) electrochemiluminescence validated (V-PLEX) system.
Measured: From 1 hour prior to intervention to 6 hours post-intervention
Concentration of serum C-reactive protein (CRP)
Serum samples will be used to analyze high sensitive CRP (hs-CRP) levels using latex-enhanced immunonephelometric test.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Concentration of serum free cortisol
Serum samples will be used to analyze the concentration of free cortisol in the circulation using electrochemiluminescence.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Concentration of plasma Adrenocorticotropic Hormone (ACTH)
Plasma samples will be used to analyze the concentration of ACTH in the circulation using electrochemiluminescence.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Pulse rate
To monitor the participants' condition and response to the treatment, pulse rate will be recorded every hour. Pulse rate will be measured using a pulse oximeter and/or digital sphygmomanometer and recorded in beats per minute.
Measured: From 1 hour prior to intervention to 6 hours post-intervention
Systolic blood pressure
To monitor the participants' condition and response to the treatment, systolic blood pressure will be recorded every hour. Systolic blood pressure will be measured using a digital sphygmomanometer and recorded in millimeters of mercury (mmHg).
Measured: From 1 hour prior to intervention to 6 hours post-intervention
Diastolic blood pressure
To monitor the participants' condition and response to the treatment, diastolic blood pressure will be recorded every hour. Diastolic blood pressure will be measured using a digital sphygmomanometer and recorded in millimeters of mercury (mmHg).
Measured: From 1 hour prior to intervention to 6 hours post-intervention
Body temperature
To monitor the participants' condition and response to the treatment, body temperature will be recorded every hour. Temperature will be taken in the ear using a tympanic thermometer and recorded in degrees of Celsius (°C).
Measured: From 1 hour prior to intervention to 6 hours post-intervention
Scoring of the Generic Assessment of Side Effects (GASE) questionnaire
General side effects will be assessed and recorded in a structured, validated approach using the Generic Assessment of Side Effects (GASE). The GASE consists of 36 items asking for most frequently reported side effects for drugs based on the FDA adverse event reporting system database from all countries. Symptoms of all body parts during the last seven days will be self-reported and rated based on severity from 0 (not present) to 3 (severe).
Measured: From 1 hour prior to intervention to 7 days post-intervention
Scoring of the Sickness Questionnaire (SicknessQ)
To comprehensively measure sickness behaviour during the test day, the Sickness Questionnaire (SicknessQ) will be used. The SicknessQ is a brief and psychometrically sound assessment instrument to measure perceived sickness behaviour. It is sensitive to LPS challenge and was developed based on acute sickness response to LPS endotoxemia in healthy individuals. The SicknessQ score was significantly increased by LPS challenge compared to placebo at 1.5 hours post-injection and subsided to non-significant levels after 4.5 hours. In addition, the increase in SicknessQ score was partly mediated by the relative increase in inflammatory cytokines.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the State-Trait Anxiety Inventory, State Anxiety subscale (STAI-S)
To measure momentary anxiety during the test day, the STAI-S will be used. This inventory is part of the State-Trait Anxiety Inventory (STAI). The STAI is a psychological inventory that measures two types of anxiety - state anxiety and trait anxiety. State anxiety is anxiety about an event, while trait anxiety is the level of anxiety related to an individual's character. The inventory consists of 40 questions, with 20 questions specifically for state anxiety, rated on a 4-point scale. State anxiety is rated with anxiety absent and anxiety present questions. Anxiety absent questions constitute the absence of anxiety in a statement like, "I feel secure." Anxiety present questions represent the presence of anxiety in a statement like "I feel worried." The 4-point scale are as follows: 1 'not at all', 2 'somewhat', 3 'moderately so', and 4 'very much so'.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the State-Trait-Anxiety and Depression Scale (STADI)
The State-Trait Anxiety-Depression Inventory aims to recognize and differentiate symptoms of anxiety and depression. It consists of 40 self-report items that distinguish between temporary (state) and chronic conditions (trait). The rating scale consists of a 4-point Likert-type scale ranging from 1 (not at all) to 4 (very much). The STADI has a 4-factor structure of anxiety and depression including emotionality, worry, dysthymia, and anhedonia.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Stanford Sleepiness Scale (SSS)
The Stanford Sleepiness Scale (SSS) is a self-report questionnaire that aims to quickly assess the levels of sleepiness throughout the day and track overall alertness at each hour of the day. It is commonly used in research and clinical settings to assess the effectiveness of a specific treatment. The scale is rated from 1 to 7 with 1 being wide awake and 7 being sleep onset. A rate of X is given if the respondent is asleep.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Positive and Negative Affect Schedule (PANAS)
The PANAS consists of two 10-item mood scales and was developed to provide brief measures of negative affect (NA) and positive affect (PA). NA and PA reflect dispositional dimensions, with high-NA epitomized by subjective distress and unpleasurable engagement, and low-NA by the absence of these feelings. By contrast, PA represents the extent to which an individual experiences pleasurable engagement with the environment. Thus, emotions such as enthusiasm and alertness are indicative of high-PA, whilst lethargy and sadness characterize low-PA. Respondents are asked to rate the extent to which they have experienced each particular emotion within a specified time period, on a 5-point scale. The scale points are: 1 'very slightly or not at all', 2 'a little', 3 'moderately', 4 'quite a bit', and 5 'very much'.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Multidimensional Mood Questionnaire (MDMQ)
The MDMQ is a well-validated 24-item questionnaire commonly used to quickly evaluate the mental state and mood of a respondent. It consists of 24 items to measure three current psychological states in bipolar dimensions of: good vs. bad, awake vs. tired, and calm vs. nervous. Each item is rated with a 5-point rating scale. The results range between 1 (feeling bad, tired, nervous) and 40 points (feeling good, awake, calm) for each dimension, summing up to an overall maximum count of 120 points (maximum scores for feeling good, awake, and calm) for the whole questionnaire.
Measured: From 1 hour prior to intervention to 24 hours post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start3 May 2024
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InflammationStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lukas Van Oudenhove, Universitaire Ziekenhuizen KU Leuven
- Investigators
- Lukas Van Oudenhove, MD, PhD, Principal investigator, KU LeuvenKristin Verbeke, Pharm, PhD, Principal investigator, KU LeuvenBoushra Dalile, PhD, Principal investigator, KU Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620679
- Sponsor's protocol ID
- S67872
- Other IDs
- 101002525
- Acronym
- INFLAMES
- Status last verified
- Sep 2024
- First submitted
- 24 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data (IPD) that underlie results in a publication will be made available to other researchers with all identifying information removed.
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men
- ClinicalTrials.gov ID
- NCT06620679
- Acronym / sponsor ID
- INFLAMES / S67872
- Conditions
- Inflammation, Stress, Healthy Volunteer
- Keywords
- Inflammation, Stress, Lipopolysaccharide (LPS), Short-chain fatty acids, Neuroimaging
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenUniversity, hospital or other
- Study start
- 3 May 2024 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional study is to determine the effects of inflammation on stress responses in the brain of healthy men. In order to achieve this goal, participants are injected with an inflammation-inducing agent, then observed inside a brain scanner.
Detailed description
This interventional study is a randomized, triple-blind, placebo-controlled, cross-over study aiming to elucidate the impact of acute laboratory-induced inflammation using lipopolysaccharide (LPS) on stress responses in the brain of healthy men. Acute stress responses to a psychological task, the Maastricht Imaging Stress Task (MIST), are observed via blood-oxygenation-level-dependent functional magnetic resonance imaging (BOLD fMRI) and simultaneous positron emission tomography (PET) imaging using the radiotracer 18 Fluor (18F)-N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-acetamide (DPA)-714, which targets the 18 kilodalton (kDA) translocator protein (TSPO) of activated microglia. Every participant will receive 0.4 ng/kg body weight of LPS and saline on separate treatment visits, separated by a 2-3 months wash-out period.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LPS then Saline | Experimental | Biological: Lipopolysaccharide (LPS), Other: PlaceboA crossover arm where the participant first receives the intervention (LPS), undergoes a wash-out period, then receives the placebo (saline). |
| Saline then LPS | Experimental | Biological: Lipopolysaccharide (LPS), Other: PlaceboA crossover arm where the participant first receives the placebo (saline), undergoes a wash-out period, then receives the intervention (LPS). |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male
- Healthy
- Age 18-45 years
- BMI 18.5-25 kg/m2
- Proficient in English and/or Dutch
Key exclusion criteria (17 listed)
- Have previous or current neuropsychiatric disorders or have history of major head trauma
- Have any disorder, which in the Investigator's opinion might jeopardise your safety or compliance with the study
- Have any prior or current treatment(s) that might jeopardise your safety or that would compromise the integrity of the study
- Have any prior and recent medication use (especially antibiotics, cardiovascular drugs, steroids, non-steroid anti-inflammatory drugs, centrally effective drugs)
- Are participating in an interventional Trial with an investigational medicinal product (IMP) or device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lipopolysaccharide (LPS)Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight | Biological | LPS then Saline, Saline then LPS |
| PlaceboNormal saline, single i.v. bolus, in equal volume to intervention | Other | LPS then Saline, Saline then LPS |
Primary outcome
Blood-oxygenation-level-dependent functional magnetic resonance imaging (BOLD fMRI) response to acute stress task
Time frame: 2 hours after the single i.v bolus administration of LPS or saline
BOLD fMRI responses to the Montreal Imaging Stress Task (MIST) after administration of LPS compared to saline
Binding potential of [18F]-DPA-714 radiotracer
Time frame: 2 hours after the single i.v bolus administration of LPS or saline
The change in [18F]-DPA-714 binding potential with and without LPS administration (%∆BPND)
15 secondary outcomes
Concentration of serum cytokines
Time frame: From 1 hour prior to intervention to 6 hours post-intervention
Concentration of serum C-reactive protein (CRP)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Concentration of serum free cortisol
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Concentration of plasma Adrenocorticotropic Hormone (ACTH)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Pulse rate
Time frame: From 1 hour prior to intervention to 6 hours post-intervention
Systolic blood pressure
Time frame: From 1 hour prior to intervention to 6 hours post-intervention
Diastolic blood pressure
Time frame: From 1 hour prior to intervention to 6 hours post-intervention
Body temperature
Time frame: From 1 hour prior to intervention to 6 hours post-intervention
Scoring of the Generic Assessment of Side Effects (GASE) questionnaire
Time frame: From 1 hour prior to intervention to 7 days post-intervention
Scoring of the Sickness Questionnaire (SicknessQ)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the State-Trait Anxiety Inventory, State Anxiety subscale (STAI-S)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the State-Trait-Anxiety and Depression Scale (STADI)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Stanford Sleepiness Scale (SSS)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Positive and Negative Affect Schedule (PANAS)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Scoring of the Multidimensional Mood Questionnaire (MDMQ)
Time frame: From 1 hour prior to intervention to 24 hours post-intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) that underlie results in a publication will be made available to other researchers with all identifying information removed.
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lukas Van Oudenhove, MD, PhD principal investigator
KU Leuven
Kristin Verbeke, Pharm, PhD principal investigator
KU Leuven
Boushra Dalile, PhD principal investigator
KU Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lipopolysaccharide (LPS) in people with Inflammation and Stress, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lukas Van Oudenhove, MD, PhD (+3216330147, lukas.vanoudenhove@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood-oxygenation-level-dependent functional magnetic resonance imaging (BOLD fMRI) response to acute stress task (time frame: 2 hours after the single i.v bolus administration of LPS or saline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.